Immatics N.V. Ordinary Shares IMTX
$9.56
+1.06%
at last close
Market Cap$1.44 billion
P/E Ratio—
Div Yield—
Volume519.8K
52-Week Range
$5.05$12.41
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $21.25 (+122.3% upside)
Key Stats
- Today's Range
- $9.30 – $9.57
- 50-Day Range
- $8.17 – $10.89
- 52-Week Range
- $5.05 – $12.41
- Volume
- 520K shs
- Average Volume
- 582K shs
- Market Cap
- $1.44 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About Immatics N.V. Ordinary Shares
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Related Stocks
Compare head-to-head: IMTX vs NVDA·IMTX vs AAPL·IMTX vs GOOGL·IMTX vs GOOG
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.